Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: A longitudinal, randomized trial in young Ugandan children
Clinical Infectious Diseases, Volume 49, No. 11, Year 2009
Notification
URL copied to clipboard!
Description
Background: Artemisinin-based combination therapies are now widely recommended as first-line treatment for uncomplicated malaria. However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children. Methods: A total of 351 children aged 6 weeks to 12 months were enrolled and followed up for up to 1 year. Children who were at least 4 months of age, weighted at least 5 kg, and had been diagnosed as having their first episode of uncomplicated malaria were randomized to receive artemether- lumefantrine or dihydroartemisininpiperaquine. The same treatment was given for all subsequent episodes of uncomplicated malaria. Recrudescent and new infections were distinguished by polymerase chain reaction genotyping. Outcomes included the risk of recurrent malaria after individual treatments and the incidence of malaria treatments for individual children after randomization. Results: A total of 113 children were randomized to artemether-lumefantrine and 119 to dihydroartemisininpiperaquine, resulting in 320 and 351 treatments for uncomplicated falciparum malaria, respectively. Artemetherlumefantrine was associated with a higher risk of recurrent malaria after 28 days (35% vs 11%; P ≤ .001). When the duration of follow-up was extended, differences in the risk of recurrent malaria decreased such that the overall incidence of malaria treatments was similar for children randomized to artemether-lumefantrine, compared with those randomized to dihydroartemisinin-piperaquine (4.82 vs 4.61 treatments per person-year; P=.63). The risk of recurrent malaria due to recrudescent parasites was similarly low in both treatment arms. Conclusions: Artemether-lumefantrine and dihydroartemisinin-piperaquine were both efficacious and had similar long-term effects on the risk of recurrent malaria. © 2009 by the Infectious Diseases Society of America. All rights reserved.
Authors & Co-Authors
Arinaitwe, Emmanuel S.
Uganda, Kampala
Makerere University
Sandison, Taylor G.
United States, Seattle
University of Washington
Wanzira, Humphrey
Uganda, Kampala
Makerere University
Kakuru, Abel
Uganda, Kampala
Makerere University
Homsy, Jaco
United States, Atlanta
Centers for Disease Control and Prevention
Kalamya, Julius Namonyo
United States, Atlanta
Centers for Disease Control and Prevention
Kamya, Moses Robert K.
Uganda, Kampala
School of Medicine, Makerere University College of Health Sciences
Vora, Neil M.
United States, San Francisco
Ucsf School of Medicine
Greenhouse, Bryan R.
United States, San Francisco
Ucsf School of Medicine
Rosenthal, Philip Jon
United States, San Francisco
Ucsf School of Medicine
Tappero, Jordan W.
United States, Atlanta
Centers for Disease Control and Prevention
Dorsey, Grant M.
United States, San Francisco
Ucsf School of Medicine
Statistics
Citations: 118
Authors: 12
Affiliations: 5
Identifiers
Doi:
10.1086/647946
ISSN:
10584838
Research Areas
Infectious Diseases
Maternal And Child Health
Study Design
Randomised Control Trial
Cohort Study